

# Laura Palmeri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6339066/publications.pdf>

Version: 2024-02-01

12  
papers

1,720  
citations

933447

10  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

3351  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 738-746.	10.7	778
2	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
3	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , 2019, 73, 41-53.	7.7	69
4	Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. <i>Cancer</i> , 2006, 107, 2898-2905.	4.1	51
5	Regulatory Cytokine Gene Polymorphisms and Risk of Colorectal Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 98-103.	3.8	39
6	Cytokine Gene Polymorphisms and Breast Cancer Susceptibility. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 104-109.	3.8	37
7	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, 213-221.	2.3	31
8	Should cirrhosis change our attitude towards treating non- $\alpha$ hepatic cancer?. <i>Liver International</i> , 2012, 32, 21-27.	3.9	21
9	Weekly docetaxel in the treatment of metastatic breast cancer. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1047-1059.	2.0	19
10	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , 2017, 12, 525-533.	3.6	15
11	Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 94-98.	2.0	11
12	High efficacy of the CHOP + rituximab association in a case of primary rectal non-Hodgkin lymphoma (NHL). <i>Leukemia and Lymphoma</i> , 2006, 47, 1686-1687.	1.3	1